Teijin (3401) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
2 Oct, 2026Executive summary
Q1 FY2024 revenue rose 11.5% YoY to ¥255.3B; adjusted operating income increased 115.7% to ¥10.4B, and profit attributable to owners rose 110.2% to ¥4.5B.
Profit was ¥5.2B versus ¥2.7B a year earlier.
IFRS was adopted from FY2024, with prior results restated for comparability.
Infocom’s planned divestiture led to its classification as a discontinued operation and its assets and liabilities as held for sale.
Financial highlights
Q1 EBITDA was ¥29.3B, up 22.0% YoY; depreciation and amortization was ¥19.3B, down 1.2%.
Gross profit increased to ¥63.4B from ¥58.3B, and operating income rose to ¥8.0B from ¥4.6B.
Profit before tax rose 58.8% to ¥8.4B; basic EPS doubled to ¥23.12 from ¥11.01.
Finance income and costs swung to a ¥1.6B expense from ¥0.6B income, mainly on lower foreign-exchange gains, including derivative valuation gains.
Operating cash flow improved to ¥8.6B from negative ¥5.9B; free cash flow was negative ¥8.4B versus negative ¥21.3B.
Outlook and guidance
FY2024 revenue forecast is ¥1,010B and adjusted operating income ¥23B; versus the prior outlook, these are increases of ¥35B and ¥3B.
FY2024 operating income is forecast at ¥19B; profit attributable to owners, EPS and free cash flow remain undetermined.
Annual dividend forecast remains ¥30 per share, split between ¥15 interim and ¥15 year-end.
FY2024 assumptions include ¥151/$, ¥162/€, Dubai crude at $82/barrel and European natural gas at €35/MWh.
Latest events from Teijin
- Profit and AOI surged on asset sales, with higher outlook and ongoing segment reorganization.3401
Q1 2027 - Aiming for customer-driven growth, profitability, and strong ESG performance by FY2028.3401
Investor presentation - FY2026 targets profit recovery and growth amid restructuring and stable dividends.3401
Q4 2026 - Innovative materials and a niche-focused strategy target rapid growth in batteries, semiconductors, and hydrogen.3401
Investor presentation - Revenue and profit fell on impairments and divestitures, but Healthcare grew and dividend is stable.3401
Q3 2026 - Protect PC earnings while scaling non-PC growth, high-value products and circular materials.3401
Investor Day 2025 - Q1 revenue and adjusted income declined; FY2025 guidance and the ¥50 dividend remain unchanged.3401
Q1 2026 - Focus on home healthcare, rare diseases, and innovation drives long-term growth.3401
Investor Update - A composites impairment drove a first-half loss as FY2024 guidance and dividends rose.3401
Q2 2025